ClinicalTrials.gg

Program

adagrasib

Also written as “Adagrasib”, “MRTX849” and “Eltrombopag + adagrasib”.

Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Biliary Tract Neoplasms, led by 2 companies.

Furthest: phase 3, since Oct 28, 202016 company-led studies, 7 open or runningNext primary completion: Feb 16, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb157 open or runningphase 3since Oct 28, 2020Dec 18, 2018Feb 16, 2028phase 2 · NCT07415031
Zai Lab10 open or runningphase 1since Jan 13, 2022Jan 13, 2022none ahead

Also a collaborator on its studies: aadi-bioscience-inc, Novartis and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Dec 18, 2018.

  1. Oct 28, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT04613596 · 626 planned · United States, Argentina, Australia and more
  2. Dec 21, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT04685135 · 453 enrolled · United States, Australia, Austria and more
  3. Mar 2, 2021Phase 3 study in Colorectal NeoplasmsBristol-Myers Squibb · NCT04793958 · 461 enrolled · United States, Argentina, Australia and more
  4. Jul 6, 2021Phase 1 study in Neoplasm MetastasisBristol-Myers Squibb · NCT04975256 · 7 enrolled · United States
  5. Dec 1, 2021Phase 1 study in Advanced Solid TumorBristol-Myers Squibb · NCT05178888 · 11 enrolled · United States
  6. Jan 13, 2022Zai Lab's first study: phase 1 study in Neoplasm MetastasisNew to Zai LabZai Lab · NCT05263986 · 22 enrolled · China
  7. Apr 12, 2023Phase 2 study in Neoplasm MetastasisBristol-Myers Squibb · NCT05853575 · 200 enrolled · United States, Brazil, Croatia and more
  8. Apr 12, 2023Phase 1 study in Neoplasm MetastasisBristol-Myers Squibb · NCT05840510 · 6 enrolled · United States
  9. Jun 20, 2023Phase 1 study in Healthy AdultsBristol-Myers Squibb · NCT05924152 · 16 enrolled · United States
  10. Aug 29, 2023Phase 2 study in Biliary Tract NeoplasmsBristol-Myers Squibb · NCT06024174 · 5 enrolled · United States, Australia, Finland and more
  11. Jan 24, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT06801418 · 160 enrolled · United States
  12. Mar 7, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06875310 · 630 planned · United States, Argentina, Australia and more
  13. Feb 11, 2026Phase 2 study in Solid TumorsBristol-Myers Squibb · NCT07415031 · 170 planned · United States, Australia, Belgium and more
  14. Jul 20, 2026Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT07723118 · 10 enrolled · United States

Ahead

  1. Feb 16, 2028Primary completion: phase 2 study in Solid TumorsBristol-Myers Squibb · NCT07415031
  2. Oct 31, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT04613596
  3. Sep 7, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06875310

TargetBeta

KRAS →read by rule
“An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
“GTPase KRas inhibitor”ChEMBL 37, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07723118Healthy Participants · United States1CompletedBristol-Myers SquibbSep 8, 202610
NCT07415031Solid Tumors · United States, Australia, Belgium and more2RecruitingBristol-Myers SquibbFeb 16, 2028170
NCT06875310Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbSep 7, 2029630
NCT06801418Healthy Volunteers · United States1CompletedBristol-Myers SquibbJun 19, 2025160
NCT06024174Biliary Tract Neoplasms · United States, Australia, Finland and more2TerminatedBristol-Myers SquibbMay 13, 20245
NCT05924152Healthy Adults · United States1CompletedBristol-Myers SquibbAug 9, 202316
NCT05853575Neoplasm Metastasis · United States, Brazil, Croatia and more2Active, not recruitingBristol-Myers SquibbOct 30, 2026200
NCT05840510Neoplasm Metastasis · United States1TerminatedBristol-Myers SquibbDec 27, 20246
NCT05263986Neoplasm Metastasis · China1UNKNOWNZai LabOct 31, 202322
NCT05178888Advanced Solid Tumor · United States1CompletedBristol-Myers SquibbJun 15, 202311
NCT04975256Neoplasm Metastasis · United States1TerminatedBristol-Myers SquibbNov 2, 20227
NCT04793958Colorectal Neoplasms · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbJan 16, 2026461
NCT04685135Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3Active, not recruitingBristol-Myers SquibbDec 30, 2023453
NCT04613596Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbOct 31, 2028626
NCT04330664Neoplasm Metastasis · United States1CompletedBristol-Myers SquibbJul 29, 202286
NCT03785249Neoplasm Metastasis · United States, Puerto Rico2Active, not recruitingBristol-Myers SquibbJun 23, 2026731

How it is read

Names in the registry

  • “Adagrasib”, 12 entries
  • “MRTX849”, 7 entries
  • “Eltrombopag + adagrasib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.